What Is the Newest Weight Loss Injection Called?

How clinical trials shaped what we now call the newest injection

The SURMOUNT programme set the benchmark. In SURMOUNT-1 (2,539 adults with obesity but without type 2 diabetes, followed for 72 weeks) participants taking the 15mg dose of tirzepatide lost an average of around 20–21% of body weight. That figure came from a paper published in the New England Journal of Medicine and was central to NICE's decision to recommend tirzepatide in its technology appraisal TA1026. It is worth pausing on the number: before tirzepatide, the best-evidenced injection for weight management (semaglutide (Wegovy) at 2.4mg) produced average losses of around 15% over 68 weeks. Tirzepatide's results in SURMOUNT-5, a direct head-to-head trial published in the NEJM in 2025, showed greater average weight reduction than semaglutide 2.4mg in adults with obesity and no diabetes. That evidence base is why clinicians and regulators describe tirzepatide as a step forward rather than a routine update. If you are wondering what the new weight loss injection is called and why it keeps appearing in the news, the headline numbers matter, but so does what they represent: meaningful, sustained changes in body weight for people who had often tried other approaches without comparable results.

What makes it different from older weight loss injections

To understand why tirzepatide is described as new in a meaningful sense, it helps to look at what was available before it. Semaglutide (Wegovy) (the previous generation of weight loss injection) works by activating GLP-1 receptors, which slow gastric emptying, increase feelings of fullness and reduce appetite. Tirzepatide does all of that and also activates GIP receptors, a second gut-hormone pathway involved in energy balance and fat metabolism. Whether you are exploring all available weight loss injections or trying to understand the difference a single receptor makes in practice, the dual mechanism appears to be what drives the larger average weight loss in trials. The injection itself is a once-weekly subcutaneous injection, given via a pre-filled KwikPen into the abdomen, thigh or upper arm, with the site rotated each week. Treatment starts at 2.5mg (a dose whose job is letting the body adjust rather than producing immediate weight loss) and is increased gradually by the prescriber. The licensed strengths in the UK run from 2.5mg up to 15mg. One practical habit worth building early: check the pen's expiry date and confirm it has been refrigerated correctly before each use, it takes under a minute and is one of the simplest ways to protect your treatment.

Who the evidence says this injection is for, and what a prescriber weighs up

NICE's recommendation (TA1026) covers adults with a BMI of 35 or above plus at least one weight-related condition such as high blood pressure, type 2 diabetes, obstructive sleep apnoea, dyslipidaemia or cardiovascular disease. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance, NICE sets the adjustment at 2.5 kg/m² lower for South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds. For private prescribing, the licensed criteria are broader: a BMI of 30 or above, or 27 or above with at least one relevant condition. You can read more about how weight management treatment options are assessed on our overview page. A prescriber's job is not simply to check a BMI figure; they look at your full health picture, any medicines you already take, contraindications, and whether tirzepatide is the right fit for you specifically. That review is why the consultation exists. If you are curious about how these questions are handled in practice, our clinical team page explains our prescribing approach. The NICE TA1026 guidance also sets out what ongoing review looks like: if less than 5% weight loss has been achieved after six months at the highest tolerated dose, the prescriber is expected to reassess whether continuing is appropriate.

How to access Mounjaro safely, NHS, private, and why it matters

On the NHS, tirzepatide is being introduced in a phased rollout: from June 2025 for adults with a BMI of 40 or above and four or more qualifying conditions, expanding gradually over subsequent cohorts. Waiting lists through NHS specialist services are common, and not everyone who is clinically suitable will qualify at the current phase. A regulated private pharmacy is the route many people take when they do not yet meet NHS criteria or prefer not to wait. If you are comparing your options, our page on new weight loss injections covers the landscape clearly. The safety of that private route depends entirely on where you get it. The MHRA has warned repeatedly about counterfeit weight loss pens sold online, including fake tirzepatide pens seized in a raid on an illicit UK manufacturing site in 2025. Our dedicated pages covering men's weight loss injections and what the weight loss injection is called can help you feel more confident that you are researching the right treatment before you buy. The straightforward check: any legitimate online pharmacy must be registered with the GPhC, you can verify nume's registration directly on the GPhC register. Pharmacies that supply prescription-only medicines without conducting a proper clinical assessment are not operating legally, and the medicines they supply may not be genuine. At nume, a GPhC-registered Independent Prescriber reads every consultation personally on the same day it is submitted. If you would like to talk through whether tirzepatide is suitable for you, you can speak to our prescribers through a free consultation, no referral, no waiting list, and your answers are reviewed by a real clinician, not software.